240 related articles for article (PubMed ID: 26169448)
1. Mental health status of varenicline and bupropion users during a quit attempt compared to current smokers, other quitters, and non-smokers.
Shewale AR; Borse MS; Brown JD; Li C
Drug Alcohol Depend; 2015 Sep; 154():132-8. PubMed ID: 26169448
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
Anthenelli RM; Benowitz NL; West R; St Aubin L; McRae T; Lawrence D; Ascher J; Russ C; Krishen A; Evins AE
Lancet; 2016 Jun; 387(10037):2507-20. PubMed ID: 27116918
[TBL] [Abstract][Full Text] [Related]
3. Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States.
Shah D; Shah A; Tan X; Sambamoorthi U
Drug Alcohol Depend; 2017 Aug; 177():187-193. PubMed ID: 28605678
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.
Anthenelli RM; Gaffney M; Benowitz NL; West R; McRae T; Russ C; Lawrence D; St Aubin L; Krishen A; Evins AE
J Gen Intern Med; 2019 Jun; 34(6):862-870. PubMed ID: 30847828
[TBL] [Abstract][Full Text] [Related]
5. Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers.
Zhu SH; Cummins SE; Gamst AC; Wong S; Ikeda T
Tob Control; 2016 Jul; 25(4):464-9. PubMed ID: 26283713
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers.
Yang M; Chen H; Johnson ML; Essien EJ; Peters RJ; Wu IH; Abughosh SM
Subst Use Misuse; 2015; 50(13):1628-37. PubMed ID: 26595661
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease.
Kotz D; Viechtbauer W; Simpson CR; van Schayck OCP; West R; Sheikh A
Thorax; 2017 Oct; 72(10):905-911. PubMed ID: 28473506
[TBL] [Abstract][Full Text] [Related]
8. Use of stop-smoking medications in the United States before and after the introduction of varenicline.
Kasza KA; Cummings KM; Carpenter MJ; Cornelius ME; Hyland AJ; Fong GT
Addiction; 2015 Feb; 110(2):346-55. PubMed ID: 25331778
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study.
Carney G; Bassett K; Maclure M; Taylor S; Dormuth CR
Addiction; 2020 Aug; 115(8):1534-1546. PubMed ID: 32077187
[TBL] [Abstract][Full Text] [Related]
10. Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis.
Peckham E; Brabyn S; Cook L; Tew G; Gilbody S
BMC Psychiatry; 2017 Jul; 17(1):252. PubMed ID: 28705244
[TBL] [Abstract][Full Text] [Related]
11. Use of varenicline versus bupropion and risk of psychiatric adverse events.
Pasternak B; Svanström H; Hviid A
Addiction; 2013 Jul; 108(7):1336-43. PubMed ID: 23445269
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance Assessment of Cardiac Implications of Nicotine Replacement Therapy Among Smokers.
Olawuyi O; Mathieson K
Curr Drug Saf; 2020; 15(3):173-180. PubMed ID: 32525783
[TBL] [Abstract][Full Text] [Related]
13. Varenicline in the management of smoking cessation: a single technology appraisal.
Hind D; Tappenden P; Peters J; Kenjegalieva K
Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study.
Kotz D; Viechtbauer W; Simpson C; van Schayck OC; West R; Sheikh A
Lancet Respir Med; 2015 Oct; 3(10):761-8. PubMed ID: 26355008
[TBL] [Abstract][Full Text] [Related]
15. Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies.
Steinberg MB; Bover MT; Richardson DL; Schmelzer AC; Williams JM; Foulds J
Drug Alcohol Depend; 2011 Mar; 114(1):77-81. PubMed ID: 20951511
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with the use of aids to cessation in English smokers.
Kotz D; Fidler J; West R
Addiction; 2009 Aug; 104(8):1403-10. PubMed ID: 19549267
[TBL] [Abstract][Full Text] [Related]
17. An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion.
Etter JF; Schneider NG
Nicotine Tob Res; 2013 Jan; 15(1):59-68. PubMed ID: 22529220
[TBL] [Abstract][Full Text] [Related]
18. Emotional disorders and smoking: relations to quit attempts and cessation strategies among treatment-seeking smokers.
Zvolensky MJ; Farris SG; Leventhal AM; Ditre JW; Schmidt NB
Addict Behav; 2015 Jan; 40():126-31. PubMed ID: 25260199
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of varenicline versus nicotine replacement therapy in patients with and without psychiatric disorders.
Kaduri P; Voci S; Zawertailo L; Chaiton M; McKenzie K; Selby P
J Addict Med; 2015; 9(3):169-76. PubMed ID: 25622124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
